SanBio Company (4592) Q4 2026 earnings summary

Executive summary

• Advanced regenerative medicine sector with key product AKUUGO® receiving conditional approval in Japan for traumatic brain injury; first shipment expected in the second half of FY2027.1.

• Focused on expanding clinical trials in the US and Japan for chronic traumatic brain injury and ischemic stroke.

• Significant R&D investment and ongoing preparations for manufacturing, logistics, and sales infrastructure.

Financial highlights

• Operating loss of ¥3,794 million, ordinary loss of ¥4,291 million, and net loss attributable to owners of parent of ¥3,842 million for FY2026.1, all increasing year-over-year.

• Research and development expenses totaled ¥2,678 million, primarily related to AKUUGO® approval activities.

• Comprehensive income was negative ¥3,520 million.

• No dividends declared for FY2026.1; no dividend forecast for FY2027.1.

Outlook and guidance

• FY2027.1 forecast: operating loss of ¥5,625 million, ordinary loss of ¥5,632 million, and net loss of ¥5,635 million, reflecting expenses for AKUUGO® launch and infrastructure.

• No operating revenue from AKUUGO® included in forecast pending price determination.

• Continued focus on R&D and clinical trial expansion in Japan and the US.